Close Menu

NEW YORK (360Dx) – Immunodiagnostics firm Singulex announced today that it has formed a strategic collaboration with Qiagen to develop companion diagnostics.

Under the terms of the deal, Qiagen will combine Singulex's single-molecule counting (SMC) technology with its own molecular testing services to develop companion diagnostics. Qiagen will also have access to Singulex's CLIA lab. The companies aim to collaborate in a range of disease applications, Singulex said.

Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.